Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Patients with a Rising PSA after Surgery for Prostate Cancer

Objectives: This randomized phase III trial has three arms. The control group receives prostate bed radiotherapy (PBRT) alone after surgery. In one experimental arm, men receive PBRT, short-term androgen-deprivation therapy, and pelvic lymph node radiation therapy; in another they are given PBRT and short-term androgen-deprivation therapy without pelvic lymph node radiation therapy. Freedom from disease progression is the primary outcome measure.

Key entry or exclusion criteria: Lymph node dissection is not required but patients known to have positive nodes are not eligible.

Locations: 438 sites.

Goal: 1,764 patients.

Study sponsor: Radiation Therapy Oncology Group in collaboration with the National Cancer Institute.

Link for more information: clinicaltrials.gov/ct2/show/NCT00567580

NIH clinical trials identifier: NCT00567580

Objectives: This randomized phase III trial has three arms. The control group receives prostate bed radiotherapy (PBRT) alone after surgery. In one experimental arm, men receive PBRT, short-term androgen-deprivation therapy, and pelvic lymph node radiation therapy; in another they are given PBRT and short-term androgen-deprivation therapy without pelvic lymph node radiation therapy. Freedom from disease progression is the primary outcome measure.

Key entry or exclusion criteria: Lymph node dissection is not required but patients known to have positive nodes are not eligible.

Locations: 438 sites.

Goal: 1,764 patients.

Study sponsor: Radiation Therapy Oncology Group in collaboration with the National Cancer Institute.

Link for more information: clinicaltrials.gov/ct2/show/NCT00567580

NIH clinical trials identifier: NCT00567580

Objectives: This randomized phase III trial has three arms. The control group receives prostate bed radiotherapy (PBRT) alone after surgery. In one experimental arm, men receive PBRT, short-term androgen-deprivation therapy, and pelvic lymph node radiation therapy; in another they are given PBRT and short-term androgen-deprivation therapy without pelvic lymph node radiation therapy. Freedom from disease progression is the primary outcome measure.

Key entry or exclusion criteria: Lymph node dissection is not required but patients known to have positive nodes are not eligible.

Locations: 438 sites.

Goal: 1,764 patients.

Study sponsor: Radiation Therapy Oncology Group in collaboration with the National Cancer Institute.

Link for more information: clinicaltrials.gov/ct2/show/NCT00567580

NIH clinical trials identifier: NCT00567580